Oragenics Inc
Oragenics Inc. is a U.S.-based biopharmaceutical development company focused on neurology assets, with its lead program ONP-002 being developed for the treatment of mild traumatic brain injury (concussion). The company operates as a single reportable segment centered on research, nonclinical work, clinical development, and regulatory advancement of its product candidate pipeline.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaDevelopment activities for ONP-002, the company's lead neurology candidate for concussion.
Third-party clinical trial, manufacturing, and regulatory services used to advance the program.
Internal and outsourced preclinical studies and discovery work supporting the pipeline.
Asiakkaat
Oragenics does not currently sell commercial products, so its direct counterparties are primarily clinical research organizations, manufacturing and regulatory service providers, and potential licensing or strategic partners. If ONP-002 advances, the end market would be patients and healthcare providers treating concussion and other mild traumatic brain injury cases.
They provide trial execution, manufacturing, and regulatory support for ONP-002 development.
Potential partners that could fund, co-develop, or commercialize neurology assets.
The eventual end users of a concussion treatment if the candidate reaches market.
Strategia
The company’s strategy is to advance ONP-002 through clinical development and IND-enabling work while seeking external capital and strategic partnerships to support the program. It also references licensing, joint ventures, and other business arrangements as ways to fund development and expand the pipeline.
The lead asset is the core value driver and the basis for future partnering or commercialization.
Development requires capital and the company relies on financing or collaborations to continue operations.
Additional assets can diversify scientific risk and create more partnering opportunities.
Maantiede
Oragenics is headquartered in the United States and its development activities are managed as a single operating segment without separate geographic reporting. The company’s business is tied to U.S. capital markets, U.S. clinical development, and U.S. regulatory pathways, while any future commercialization could extend to other markets through partners.
Riskit
Oragenics faces the typical risks of a clinical-stage biotechnology company: uncertain trial outcomes, regulatory delays, and dependence on external financing. The company also highlights dilution risk from equity issuance, convertible securities, and anti-dilution features, which can materially affect shareholders as it funds development.
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Korkea
ONP-002 is still in development, so efficacy, safety, or trial design issues could halt progress.
Kohdistuu: Lead program
- Regulatory approval delay or denialVaikutus: KorkeaTodennäköisyys: Korkea
The business depends on IND-enabling work and future clinical/regulatory milestones.
Kohdistuu: FDA pathway
- Financing dilutionVaikutus: KorkeaTodennäköisyys: Korkea
The company expects to raise capital through equity and debt, which can dilute existing holders.
Kohdistuu - Anti-dilution and conversion overhangVaikutus: KeskitasoTodennäköisyys: Korkea
Series H Preferred Stock terms may increase the number of shares issued on conversion.
Kohdistuu: Series H Convertible Preferred Stock
- Partnering and licensing execution riskVaikutus: KeskitasoTodennäköisyys: Korkea
Future funding and development plans depend partly on external alliances and agreements.
Kohdistuu: Strategic partnerships
Kirjanpito
Harkinnanvaraiset erätThe company depends on future financing to continue development activities.
Vaikutus: Can affect disclosure, investor perception, and liquidity analysis
Clinical and nonclinical costs are recognized as incurred and can vary by trial stage.
Vaikutus: Drives quarter-to-quarter volatility in operating loss
The company recorded a settlement-related accrual and other public-company costs.
Vaikutus: Can materially affect G&A expense and liabilities
The March 2025 promissory note was issued at an original issue discount.
Vaikutus: Affects interest expense and net loss
Financing instruments may have embedded dilution and conversion features.
Vaikutus: Can affect equity classification, share count, and dilution
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
Ocean Biomedical, Inc.
OCEA · Pharmaceutical Preparations
Protagenic Therapeutics, Inc.\new
PTIX · Pharmaceutical Preparations
Protagenic Therapeutics, Inc.
Enveric Biosciences, Inc.
ENVB · Pharmaceutical Preparations
Oric Pharmaceuticals, Inc.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
Neurogene Inc.
NGNE · Pharmaceutical Preparations
Päivitetty: 24.9.2026